A Food Effect Study of JAB-21822 in Healthy Subjects
A Phase I, Single-center, Randomized, Open-label, 2-cycle,2-period Crossover Study to Evaluate the Food Effect on the Pharmacokinetics of JAB-21822 in Healthy Subjects
Sponsor: Allist Pharmaceuticals, Inc.
Listed as NCT05875493, this PHASE1 trial focuses on Food Effect in Healthy Participants and remains completed. Sponsored by Allist Pharmaceuticals, Inc., it has been updated 8 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
May 2025 — Present [monthly]
Completed PHASE1
-
Apr 2025 — May 2025 [monthly]
Completed PHASE1
-
Sep 2024 — Apr 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Feb 2024 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 3 earlier versions
-
Sep 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE1
Status: Enrolling By Invitation → Active Not Recruiting
-
Jul 2023 — Sep 2023 [monthly]
Enrolling By Invitation PHASE1
Status: Not Yet Recruiting → Enrolling By Invitation
-
Jun 2023 — Jul 2023 [monthly]
Not Yet Recruiting PHASE1
First recorded
May 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Allist Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .